Effects of deferiprone on immune status and cytokine pattern in thalassaemia major.

Giovanni Carlo Del Vecchio, Federico Schettini, Laura Piacente, Attilio De Santis, Paola Giordano, Domenico De Mattia

Journal: Acta haematologica 2002;108(3):144-9

PMID: 12373086

Full Text on S. Karger AG, Basel, Switzerland View on PubMed

Abstract

OBJECTIVE

The present study was undertaken to evaluate the possible occurrence of immunological abnormalities in thalassaemia major patients treated with deferiprone (L1).

METHODS

Longitudinal observational cohort study.

RESULTS

The absolute number of CD8+ lymphocytes was high and the CD4/CD8 ratio low before L1 treatment; these parameters returned to normal after 3 months of L1 treatment. TNF-alpha, IL-2 and IL-2sRalpha were elevated before L1 treatment (11.83 +/- 1.75, 11.75 +/- 3.91, 1,409 +/- 621 pg/ml, respectively), while IL-6 was normal (2.58 +/- 0.79 pg/ml). After 12 months of treatment, IL-10 was higher than in previous periods, although always within the normal range. TNF-alpha, IL-2 and IL-2sRalpha returned to normal after 12, 6, and 3 months of L1 treatment, respectively.

Address: Dipartimento di Biomedicina dell'Età Evolutiva, Università di Bari, Italia.

DOI: 10.1159/000064705

Link outs

Free resources

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-CD4-1

Subscription / membership required

Full Text Sources:

https://doi.org/10.1159/000064705

MeSH Terms: Adolescent, Adult, CD4-CD8 Ratio, Child, Cohort Studies, Cytokines, Deferiprone, Humans, Immunity, Iron Chelating Agents, Male, Pyridones, Time Factors, beta-Thalassemia